Capricor Therapeutics (CAPR) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$98.6 million.
- Capricor Therapeutics' Enterprise Value fell 1592.09% to -$98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.6 million, marking a year-over-year decrease of 1592.09%. This contributed to the annual value of -$151.5 million for FY2024, which is 28370.4% down from last year.
- Capricor Therapeutics' Enterprise Value amounted to -$98.6 million in Q3 2025, which was down 1592.09% from -$122.8 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Enterprise Value ranged from a high of -$28.5 million in Q3 2023 and a low of -$151.5 million during Q4 2024
- Over the past 5 years, Capricor Therapeutics' median Enterprise Value value was -$41.9 million (recorded in 2021), while the average stood at -$61.9 million.
- Its Enterprise Value has fluctuated over the past 5 years, first surged by 3881.29% in 2023, then crashed by 31681.0% in 2025.
- Capricor Therapeutics' Enterprise Value (Quarter) stood at -$34.9 million in 2021, then dropped by 18.74% to -$41.4 million in 2022, then grew by 4.67% to -$39.5 million in 2023, then tumbled by 283.7% to -$151.5 million in 2024, then skyrocketed by 34.95% to -$98.6 million in 2025.
- Its last three reported values are -$98.6 million in Q3 2025, -$122.8 million for Q2 2025, and -$144.8 million during Q1 2025.